Select a Practice
Search by practice name or ODS code. Select a year to see income estimates, charts, domain summaries, and exports.
What's Changed in 2026/27
Total QOF points rise to 582: clinical domain 437 pts, public health 145 pts
Maximum income ceiling updated across all indicators
CHD and STIA blood pressure indicators retired; replaced by CD001 and CD002
Secondary-prevention BP income now modelled under the cardiovascular disease domain
Four new indicators introduced: HF009, DM037, OB004 and OB005
All four appear in the indicator table with full income and threshold modelling
DM034 and DM035 carry increased point values; CHOL003 reduced to 20 points
Point totals and maximum income figures updated to reflect revised weightings
VI001–VI003 now offer an improvement-payment route alongside the standard threshold
Threshold column shows both payment routes; income is modelled on the standard route
NDH003 replaces NDH002, expanding the register to include previous gestational diabetes patients
Indicator code and description updated; income modelled under the revised register definition
Income = Points × £/point × CPI × ADF × Achievement Fraction
National Reference
2026/27Select a practice above to calculate CPI- and ADF-adjusted figures. Until then, this reference table shows each indicator and a national-average income estimate based on the published £/point rate.
| Indicator | Domain | Description | Points | Threshold | National Avg Income Estimate |
|---|---|---|---|---|---|
| AF006 | clinical | Patients with atrial fibrillation in whom stroke risk has been assessed using CHA2DS2-VASc in the preceding 12 months (excluding those with a previous score of 2 or more). | 12 | 40-95% | £2,735.40 |
| BP002 | public health | Patients aged 45 or over who have a record of blood pressure in the preceding 5 years. | 15 | 50-90% | £3,419.25 |
| AF008 | clinical | Patients on the AF register with CHA2DS2-VASc score of 2 or more, prescribed a DOAC or, if unsuitable/declined, a Vitamin K antagonist. | 12 | 70-95% | £2,735.40 |
| SMOK002 | public health | Patients with specified long-term conditions whose notes record smoking status in the preceding 12 months. | 25 | 50-90% | £5,698.75 |
| CHD005 | clinical | Patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. | 7 | 56-96% | £1,595.65 |
| SMOK004 | public health | Patients aged 15 or over recorded as current smokers who have a record of offer of support and treatment within the preceding 24 months. | 12 | 40-90% | £2,735.40 |
| CD001 | clinical | Patients with CHD, stroke or TIA, aged 79 years or under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). | 41 | 40-90% | £9,345.95 |
| VI001 | public health | Babies reaching 8 months in the preceding 12 months who received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before age 8 months. | 18 | 89-96% (or improvement 5-18 percentage points) | £4,103.10 |
| CD002 | clinical | Patients with CHD, stroke or TIA, aged 80 years or over, without moderate or severe frailty, whose last BP in the preceding 12 months is 150/90 mmHg or less (or equivalent home BP). | 20 | 46-90% | £4,559.00 |
| VI002 | public health | Children reaching 18 months in the preceding 12 months who received at least 1 dose of MMR or MMRV between ages 12 and 18 months. | 18 | 86-96% (or improvement 5-23 percentage points) | £4,103.10 |
| CHOL003 | clinical | Patients on the CHD, PAD, Stroke/TIA or CKD register currently prescribed a statin or, if declined/unsuitable, another lipid-lowering therapy. | 20 | 70-95% | £4,559.00 |
| VI003 | public health | Children reaching 5 years in the preceding 12 months who received a second dose of MMR or MMRV before age 5 years. | 18 | 81-96% (or improvement 5-30 percentage points) | £4,103.10 |
| CHOL004 | clinical | Patients on the CHD, PAD or Stroke/TIA register with most recent cholesterol in the preceding 12 months at target (LDL ≤2.0 or non-HDL ≤2.6 mmol/L). | 44 | 20-50% | £10,029.80 |
| VI004 | public health | Patients who reached 80 years old in the preceding 12 months who have received shingles vaccine between ages 70 and 79 years. | 10 | 50-60% | £2,279.50 |
| HF008 | clinical | Patients with heart failure diagnosed on or after 1 April 2023, confirmed appropriately by echocardiogram or specialist assessment. | 6 | 50-90% | £1,367.70 |
| OB004 | public health | Adults living with obesity referred to a weight management programme in the QOF year. | 5 | 10-30% | £1,139.75 |
| HF007 | clinical | Patients with heart failure on the register who have had a review in the preceding 12 months including functional capacity and medication review. | 7 | 50-90% | £1,595.65 |
| OB005 | public health | Adults living with obesity eligible for shared decision-making and pharmacotherapy pathway support. | 13 | 50-80% | £2,963.35 |
| CS005 | public health | Women/people with a cervix aged 25–49 with adequate cervical screening test in the previous 3 years and 6 months. | 7 | 45-80% | £1,595.65 |
| HF009 | clinical | Patients with HFrEF currently treated with four-pillar therapy: ACEi/ARNI/ARB, beta blocker, MRA and SGLT2 inhibitor. | 12 | 20-50% | £2,735.40 |
| CS006 | public health | Women/people with a cervix aged 50–64 with adequate cervical screening test in the previous 5 years and 6 months. | 4 | 45-80% | £911.80 |
| HYP010 | clinical | Patients with hypertension aged 79 years or under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). | 38 | 40-85% | £8,662.10 |
| HYP011 | clinical | Patients with hypertension aged 80 years or over, without moderate or severe frailty, whose last BP in the preceding 12 months is 150/90 mmHg or less (or equivalent home BP). | 14 | 40-85% | £3,191.30 |
| STIA007 | clinical | Patients with non-haemorrhagic stroke or history of TIA who have a record in the preceding 12 months that an anti-platelet agent or anti-coagulant is being taken. | 4 | 57-97% | £911.80 |
| DM006 | clinical | Patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). | 3 | 57-97% | £683.85 |
| DM014 | clinical | Patients newly diagnosed with diabetes who have a record of referral to a structured education programme within 9 months of entry on to the register. | 11 | 40-90% | £2,507.45 |
| DM020 | clinical | Patients with diabetes whose latest IFCC-HbA1c in the preceding 12 months is 58 mmol/mol or less. | 17 | 35-75% | £3,875.15 |
| DM021 | clinical | Patients with diabetes, on the register, with moderate or severe frailty in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. | 10 | 52-92% | £2,279.50 |
| DM034 | clinical | Patients with diabetes and no CVD currently prescribed a statin, or where clinically unsuitable/declined, another lipid-lowering therapy. | 8 | 50-90% | £1,823.60 |
| DM035 | clinical | Patients with diabetes and established CVD currently prescribed a statin, or where clinically unsuitable/declined, another lipid-lowering therapy. | 8 | 50-90% | £1,823.60 |
| DM036 | clinical | Patients with diabetes, on the register aged 79 years and under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). | 27 | 38-90% | £6,154.65 |
| DM037 | clinical | Patients with diabetes receiving all eight annual care processes in the preceding 12 months. | 10 | 35-75% | £2,279.50 |
| AST007 | clinical | Patients with asthma on the register who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. | 20 | 45-70% | £4,559.00 |
| AST012 | clinical | Patients with a new diagnosis of asthma on or after 1 April 2025 with a record of an objective test between 3 months before or 3 months after diagnosis. | 15 | 45-80% | £3,419.25 |
| COPD010 | clinical | Patients with COPD who have had a review in the preceding 12 months including exacerbation count and MRC breathlessness score. | 9 | 50-90% | £2,051.55 |
| DEM004 | clinical | Patients with dementia who have had a face-to-face or remote care plan review in the preceding 12 months. | 14 | 35-70% | £3,191.30 |
| MH002 | clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses with a comprehensive care plan documented in the preceding 12 months. | 5 | 40-90% | £1,139.75 |
| MH003 | clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months. | 3 | 50-90% | £683.85 |
| MH006 | clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 12 months. | 3 | 50-90% | £683.85 |
| MH007 | clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months. | 3 | 50-90% | £683.85 |
| MH011 | clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses with lipids recorded in the preceding 12 months. | 7 | 50-90% | £1,595.65 |
| MH012 | clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses with glucose or HbA1c recorded in the preceding 12 months. | 7 | 50-90% | £1,595.65 |
| NDH003 | clinical | Patients with non-diabetic hyperglycaemia or previous gestational diabetes who have had HbA1c or fasting blood glucose in the preceding 12 months. | 20 | 50-90% | £4,559.00 |